Groupe la Francaise raised its position in Surgery Partners, Inc. (NASDAQ:SGRY – Free Report) by 26.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 186,088 shares of the company’s stock after purchasing an additional 39,089 shares during the period. Groupe la Francaise owned about 0.15% of Surgery Partners worth $4,137,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of SGRY. AlphaQuest LLC increased its position in Surgery Partners by 112.0% during the 1st quarter. AlphaQuest LLC now owns 1,058 shares of the company’s stock worth $25,000 after purchasing an additional 559 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Surgery Partners by 86.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,169 shares of the company’s stock worth $28,000 after buying an additional 542 shares in the last quarter. Summit Securities Group LLC purchased a new position in Surgery Partners in the 1st quarter valued at about $31,000. FNY Investment Advisers LLC acquired a new stake in shares of Surgery Partners during the second quarter valued at about $115,000. Finally, Prudential Financial Inc. purchased a new stake in shares of Surgery Partners during the second quarter worth about $219,000.
Analyst Ratings Changes
A number of research analysts recently commented on SGRY shares. Barclays reduced their price target on Surgery Partners from $24.00 to $18.00 and set an “equal weight” rating for the company in a report on Friday, November 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $36.00 target price on shares of Surgery Partners in a research note on Tuesday, October 7th. UBS Group decreased their price target on shares of Surgery Partners from $34.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Benchmark cut their price target on shares of Surgery Partners from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, November 11th. Finally, Mizuho reduced their price objective on shares of Surgery Partners from $28.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, November 17th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Surgery Partners currently has a consensus rating of “Moderate Buy” and an average price target of $27.44.
Surgery Partners Stock Up 1.7%
Shares of NASDAQ:SGRY opened at $17.04 on Thursday. The company’s fifty day moving average is $19.51 and its two-hundred day moving average is $21.36. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.72 and a current ratio of 1.88. Surgery Partners, Inc. has a 1-year low of $14.94 and a 1-year high of $26.16. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -12.53 and a beta of 1.93.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). The business had revenue of $821.50 million during the quarter, compared to analyst estimates of $823.55 million. Surgery Partners had a negative net margin of 5.21% and a positive return on equity of 2.41%. The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $0.19 earnings per share. Equities analysts anticipate that Surgery Partners, Inc. will post 0.67 EPS for the current year.
About Surgery Partners
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Recommended Stories
- Five stocks we like better than Surgery Partners
- What is MarketRank™? How to Use it
- 3 Stocks Poised to Benefit From Google’s AI Breakthough
- How to invest in marijuana stocks in 7 steps
- Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
- How to Buy Cheap Stocks Step by Step
- 3 Stocks You’ll Wish You Bought Before 2026
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.
